Acadia Pharma (ACAD) Tops Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $17.16 -0.17%
EPS Growth %: +122.2%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
ESCA, LICT, NKSH, More
EPS Growth %: +122.2%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
ESCA, LICT, NKSH, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $134.6 million versus the consensus estimate of $130.43 million.
GUIDANCE:
Acadia Pharma sees FY2022 revenue of $510-540 million, versus the consensus of $531 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Iridium Communications (IRDM) Reports In-Line Q1 EPS; offers outlook
- Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
- Marsh & McLennan (MMC) Tops Q1 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
